ONTARGET^®: New Standard in Cardio and Vascular Protection

Wednesday 18 June 2008

ONTARGET^®: New Standard in Cardio and Vascular Protection

Hypertension 2008 - The Joint Congress of the European Society of Hypertension (ESH) and the International Society of Hypertension (ISH)

After the release of the results from the landmark trial ONTARGET^®, at the American College of Cardiology in Chicago in March 2008, special attention has been focused on ARBs in general, on their use in daily clinical practice, and the potential effects they may have beyond that of blood pressure control.

At the 2008 joint congress of the European Society of Hypertension (ESH) and the International Society of Hypertension (ISH), in Berlin, Boehringer Ingelheim and Bayer Schering Pharma gathered a group of international experts from the UK, Italy, Germany and Canada to present the symposium 'ONTARGET^®: New Standard in Cardio and Vascular Protection'. This symposium was chaired Professor Thomas Unger and Professor Salim Yusuf.

The following presentations are available as webcasts under the respective links:

Welcome and introduction

Thomas Unger, Germany

Clinical evidence from ONTARGET^®: the value of an ARB and an ACE inhibitor

Peter Sleight, United Kingdom

Preventing stroke: the ONTARGET^® and PRoFESS^® trial programmes

Hans-Christoph Diener, Germany

Translating ONTARGET^® into clinical practice

Robert Ferrari, Italy

Panel Discussion

Salim Yusuf, Canada

^* Telmisartan is currently only approved for the treatment of hypertension

These webcasts follow the presentations held on occasion of the Hypertension 2008 congress between 14th - 19th June 2008. They are reproduced here for your personal information. Pursuant to our Terms of Use any sort of reproduction or downloading, in total or in part, is prohibited.